Ensysce Biosciences, Inc.
corporate_fare Company Profile
Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ENSC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-25, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ENSC spans 8-K, SCHEDULE 13D/A, 4, 8-K/A.
Recent high-impact activity:
- Nasdaq Extends Bid-Price Deadline to Feb 2027 but Flags Cy Merger as Change of Control
- Ensysce Regains Nasdaq Equity Compliance, Seeks Second Bid-Price Grace Period
- Chairman Bob Gower Discloses 6.1% Stake, Support Agreement for Cy Biopharma Merger
- Director Bob Gower makes substantial open market purchase of ENSC shares
- Ensysce Q2 Loss Widens to $2.6M, But $31M Cash Boost Extends Runway to 2027
Financial Snapshot
Short Interest & Short Volume
1.75 days to coverFINRA reported short interest of 1,205,824 shares in ENSC as of the September 15, 2026 settlement, a 15.5% decrease from the prior period — about 1.8 days to cover at its recent average daily volume. On October 2, 2026, 26.4% of ENSC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ENSC, detected from its recent SEC filings · based on capital-structure filings through 2026-05-15.
Going Concern Warning Issued · Cash Balance Plummets
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →